One woman’s journey from receiving her diagnosis to finding a treatment that helps manage her chronic skin condition.

Continued to advance three clinical programs in immune-mediated diseases: The Phase 3 ONWARD program for ESK-001 in moderate-to-severe plaque psoriasis consists of two parallel 24-week global Phase 3 ...

Research shows lifestyle changes like diet, exercise, and smoking cessation can assist with improving psoriasis outcomes and ...

Discover a recent study from 12 hospitals across China that has shed new light on personalised care for plaque psoriasis.

The Food and Drug Administration (FDA) has approved a new presentation of Selarsdi ™ (ustekinumab-aekn), a biosimilar to Stelara ® (ustekinumab), expanding the product’s indications to include ...

Researchers conducted a retrospective study to investigate the effectiveness of brodalumab for treating difficult-to-manage ...

University of Copenhagen researchers have developed a prototype patch for treating plaque psoriasis, which may simplify ...

Successful go-public transaction and over $475 million raised this year provides cash runway through multiple clinical ...

And beyond the physical symptoms, plaque psoriasis also frequently has negative effects on mental health and alters the lifestyle of those living with it. Here are five ways that this skin condition ...

When compared with placebo, vunakizumab is a safe and efficacious treatment for moderate to severe plaque psoriasis among adults.

MENLO PARK, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new standard for the ...